Major Holder Exits 13D Reporting, Sells $128M in Shares
RPRX sits 59% above its 52-week low of $34.081.
Summary
A major institutional investor has sold approximately $128 million in Royalty Pharma shares, reducing its stake below the 5% reporting threshold and filing an exit from its Schedule 13D obligations.
Key Events · Ownership and Investor Activity · RPRX
-
Major Holder Exits 13D Reporting
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have reduced their beneficial ownership to 4.8% of Royalty Pharma's Class A Ordinary Shares, triggering an exit from their Schedule 13D reporting requirements.
-
Significant Share Sales
The reporting persons sold a total of 2,383,073 shares over the 60-day period ending June 12, 2026, with an aggregate value of approximately $128 million.
-
Sales Occur Near 52-Week High
These sales took place while Royalty Pharma's stock was trading near its 52-week high, following a series of positive company announcements.
Analysis · RPRX · Life Sciences
Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini, who previously held over 5% of Royalty Pharma, have reduced their stake to 4.8% and filed an exit from their Schedule 13D reporting obligation. This indicates a strategic decision by a significant institutional investor to reduce its exposure, selling approximately $128 million worth of shares over the past 60 days. This reduction occurs during a period of positive company news and near the stock's 52-week high.
At the time of this filing, RPRX was trading at $54.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.2B. The 52-week trading range was $34.08 to $56.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.